Despite advancements in risk estimation tools, Atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of death in the U.S., costing billions in healthcare expenditures. Veradigm Network EHR data reveals critical gaps in prevention and risk management.
In this report, you’ll explore:
ASCVD risk trends across demographics and geography
The impact of real-world data on prevention strategies
Insights from the Veradigm Network that can help inform prevention strategies
Opportunities for innovation in cardiovascular care
Learn how data-driven insights can reshape ASCVD prevention.
About this email: You are receiving this message as part of your complimentary newsletter subscription to BioPharma Dive. If you no longer wish to receive the daily newsletter, you can switch to a weekly subscription or unsubscribe. See our full privacy policy. BioPharma Dive is a product of TechTarget, Inc. and its subsidiaries, 275 Grove St. Newton, MA, 02466
